|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-05-1483.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the University of Michigan Medical Center, Ann
Arbor; Children's Hospital Medical Center, Cincinnati, OH;
International Bone Marrow Transplant Registry/Autologous Bone Marrow
Transplant Registry, Health Policy Institute, Medical College of
Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha;
Case Western Reserve University, Cleveland, OH; University of Chicago,
IL.
Lymphoblastic lymphoma (LBL) is a rare, clinically aggressive
neoplasm of the young that frequently involves the bone marrow (BM)
and/or central nervous system. Because LBL is similar to acute
lymphoblastic leukemia, some centers prefer allogeneic hematopoietic stem cell (SC) transplantation to autologous SC
transplantation. We retrospectively analyzed outcomes for patients who
underwent autologous (auto, n = 128) or HLA-identical sibling
(allo, n = 76) SC transplantations from 1989 to 1998 and were
reported to International Bone Marrow Transplant Registry
(IBMTR) or Autologous Blood and Marrow Transplant Registry
(ABMTR). Allo stem cell transplant (SCT) recipients had higher
treatment-related mortality (TRM) at 6 months (18% versus
3%, P = .002), and this disadvantage persisted at 1 and
5 years. Early relapse rates after alloSC transplantation and
autoSC transplantation were similar, but significantly lower relapse
rates were observed in alloSCT recipients at 1 and 5 years (32% versus
46%, P = .05; and 34% versus 56%,
P = .004, respectively). No differences were noted in
lymphoma-free survival rates between alloSC transplantations and
autoSC transplantations (5-year rates 36% versus 39%,
P = .82). AutoSCT recipients had higher overall survival at 6 months (75% versus 59%, P = .01), but
survival did not significantly differ between the 2 groups at 1 and 5 years (60% versus 49%, P = .09; 44% versus 39%,
P = .47, respectively). Multivariate analyses to account
for confounding factors confirmed these results. Independent of SCT
type, BM involvement at the time of transplantation and disease status
more advanced than first complete remission were associated with
inferior outcomes. In summary, alloSC transplantation for LBL is
associated with fewer relapses than with autoSC transplantation, but
higher TRM offsets any potential survival benefit.
(Blood. 2003;101:2476-2482) The lymphoblastic lymphomas (LBLs) are rare,
accounting for approximately 2% of non-Hodgkin lymphomas
(NHLs).1 These high-grade lymphomas usually are composed
of precursor T cells, have a predilection for men and boys, and occur
most commonly in children, adolescents, and young adults.2
The disease is clinically aggressive, frequently involves the bone
marrow and/or central nervous system, and in many respects is
indistinguishable from acute lymphoblastic leukemia (ALL).3,4 Although patients with limited disease may fare well, the outcome for those with poor-risk features (bone marrow or
central nervous system involvement or lactate dehydrogenase [LDH] > 300 IU/L) or recurrent disease is generally less
favorable.5-7 Children have better outcomes than adults
with poor-risk disease,6-9 but recurrent disease is
infrequently cured regardless of age.10,11 Because of the
high relapse rates and low cure rates for recurrent disease, both
autologous and allogeneic hematopoietic stem cell transplantations are
used in an attempt to improve survival. Long-term overall survival
rates of 56% to 80% are reported with each approach in patients who
received transplants in first complete
remission.12-15 Prolonged remissions and long-term
survival of patients with LBL are reported after both autologous and
allogeneic transplantations for recurrent or refractory disease.
Because these studies include small numbers of patients, it is not
known which type of transplantation, if any, represents the better
therapy for patients with LBL.16-19 Some evidence supports
the existence of a graft-versus-lymphoma (GVL)
effect,20-22 but the contribution of GVL toward survival remains unclear. We undertook a retrospective study of patients who
underwent either autologous or allogeneic transplantation and analyzed
the effect of several important factors, including stem cell source,
on survival.
Data sources
The IBMTR/ABMTR collects data at 2 levels: registration and research.
Registration data include disease type, age, sex, pretransplantation disease stage and chemotherapy responsiveness, date of diagnosis, graft
type (bone marrow and/or blood-derived stem cells), high-dose conditioning regimen, posttransplantation disease progression and
survival, development of a new malignancy, and cause of death. Requests
for data on progression or death for registered patients are at 6-month
intervals. All IBMTR/ABMTR teams contribute registration data. Research
data are collected on subsets of registered patients, including
comprehensive pretransplantation and posttransplantation clinical information.
Patients
End points Primary end points were treatment-related mortality (TRM), relapse, disease-free survival (DFS), and overall survival. TRM was defined as death during a continuous complete remission or death in the first 28 days after tranplantation. Relapse was defined as persistent or recurrent disease. Patients with persistent disease were classified as relapsed at day 28, even if they did not subsequently progress. Disease-free survival was defined as survival without evidence of disease. For analyses of DFS, relapses or deaths from any cause were considered as events. For analyses of overall survival, events were deaths from any cause.Statistical analysis Patient, disease, and treatment-related variables for the autologous and HLA-identical sibling transplantation cohorts were compared using the chi-square statistic for categorical variables and the Wilcoxon test for continuous variables. Univariate probabilities of DFS and survival were calculated using the Kaplan-Meier estimator; the log-rank test was used for univariate comparisons. Patients were censored at the time of last follow-up. Probabilities of TRM and relapse were calculated using cumulative incidence curves to accommodate competing risks.27 Relapse was used as competing risk for TRM and TRM as the competing risk for relapse. Ninety-five percent confidence intervals for all probabilities and P values of pairwise comparisons were derived from point-wise estimates and were calculated using standard techniques.28 TRM, relapse, DFS, and survival after autologous versus HLA-identical sibling transplantation were evaluated in multivariate analyses using Cox proportional hazards regression to adjust for other potentially confounding differences between the cohorts. Variables considered in multivariate analysis are as follows: type of transplant, age, sex, Karnofsky performance score at transplantation, disease stage at transplantation, chemosensitivity, bone marrow involvement at transplantation, central nervous system involvement, serum LDH, initial chemotherapy given, use of total body irradiation (TBI) and growth factors, graft source, and year of transplantation. We tested the proportional hazards assumption for each factor in the Cox model using time-dependent covariates. When this indicated differential effects over time (nonproportional hazards), models were constructed breaking the posttransplantation time course into 2 periods, using the maximized partial likelihood method to find the most appropriate breakpoint. Interactions between the main effect term and all covariates were tested prior to stepwise modeling. After modeling time-varying effects and interactions, the final multivariate model was built using a forward stepwise model selection approach. Each model contained the main effect (type of transplant, HLA-identical sibling versus autologous graft) to allow adjustments for other covariates. Factors significantly associated with the outcome variable at a 5% level were kept in the final model. First-order interactions were again examined between the type of transplant and all significant prognostic factors. Adjusted probabilities for DFS and overall survival were calculated with the multivariate Cox models described previously and weighted by the sample proportion value for each prognostic factor found significant in the regression models. To validate that results applied similarly to patients treated in remission and those with more advanced disease status, the multivariate analyses were repeated for patients in first complete remission alone and for all patients not in first complete remission. Examination for center effects used a random effects or frailty model.29 All P values are 2-sided.
Patient, disease, and treatment-related characteristics There were 76 HLA-identical sibling transplantations and 128 autologous transplantations available for analysis (Table 1). Autologous transplant recipients were older, more likely to receive peripheral blood stem cells, more likely to receive transplants before 1994, and less likely to receive a TBI-containing conditioning regimen than allogeneic transplant recipients. The 2 groups did not differ significantly for other patient, disease, and treatment-related characteristics studied.
Treatment-related mortality At every time point following transplantation (Table 2), allogeneic transplant recipients were significantly more likely to die of treatment-related causes than autologous transplant recipients (Figure 1). The 5-year cumulative incidences of TRM were 25% (95% confidence interval [CI], 16%-36%) after allogeneic transplantation and 5% (95% CI, 2%-10%) after autologous transplantation; pointwise P < 0.001. Multivariate analysis revealed that donor source was the only significant predictor of TRM. Patients who received an allogeneic transplant were 6.12 [95% CI, 2.25-16.56] times more likely to die of treatment-related causes than autologous transplant recipients. The findings remained the same when the analyses were done separately for patients in first complete remission and for patients with advanced stage disease. Graft-versus-host disease (GVHD) was reported as the cause of death in only 2 (7%) of the allogeneic transplant recipients; however, the cumulative incidence of GVHD in patients who died of TRM was 47% but only 15% in those who did not, suggesting that GVHD contributed to TRM, although it was not always the proximate cause of death. Infection, pneumonitis, and organ failure accounted for most TRM for both autologous and allogeneic transplant recipients.
Relapse For the first 6 months following transplantation, there was no statistically significant difference in the likelihood of relapse or persistent LBL after autologous versus allogeneic transplantation (Table 2; Figure 2). Among patients who survived in remission for 6 months, subsequent relapse was more likely in autologous transplant recipients than in patients who received allogeneic transplants, leading to a statistically significant difference in the cumulative incidence of relapse by 1 year after transplantation. The 5-year cumulative incidences of relapse were 34% (95% CI, 23%-45%) after allogeneic transplantation and 56% (95% CI, 45%-65%) after autologous transplantation; pointwise P = .004. Multivariate analysis revealed that donor source, lymphomatous involvement of the bone marrow at transplantation, and disease status at transplantation were independent predictors of persistent or recurrent lymphoma after transplantation (Table 3). There was no statistically significant effect of acute or chronic GVHD on the risk of relapse for allogeneic transplant recipients, but low statistical power could miss a small effect.
Disease-free and overall survival Multivariate analysis of DFS found that allogeneic transplant recipients had inferior DFS for the first 6 months following transplantation and superior disease-free survival after 6 months, but these differences did not reach statistical significance (Figure 3). The 5-year adjusted probabilities of DFS were 36% (95% CI, 24%-48%) after allogeneic transplantations and 39% (95% CI, 30%-48%) after autologous transplantation; pointwise P = .82. Disease status at transplantation was more important than source of stem cells. Patients who received transplants in first complete remission had higher DFS than transplant recipients who had more advanced disease (Table 4). No other variable predicted DFS. When subgroup analyses were performed for patients in first complete remission and for patients in first complete remission without prior bone marrow involvement, the results were the same. Allogeneic transplant recipients were almost twice as likely to die during the first 6 months after transplantation compared with autologous transplant recipients. Among patients who survived the first 6 months, subsequent survival was similar for autologous and allogeneic transplant recipients (Figure 4; Table 5), but treatment failure patterns differed. Patients who received autologous grafts were more likely to die of persistent or recurrent lymphoma in the early and late posttransplantation periods than were allograft recipients. No single cause accounted for a majority of deaths after allografts; deaths from lymphoma, pneumonitis, organ failure, and GVHD were equally common. The 5-year adjusted probabilities of survival were 39% (95% CI, 29%-49%) after allogeneic transplantation and 44% (95% CI, 36%-52%) after autologous transplantation; pointwise P = .47. Advanced disease status and poor performance status at transplantation were the only other factors predictive of higher mortality (Table 5).
Hematopoietic stem cell transplantation is an option for some patients with LBL, particularly those with recurrent or refractory disease. Some investigators suggested that transplantation has a role for LBL in first complete remission,13,15 and in a prospective randomized trial recipients of an autologous transplant had superior relapse-free survival compared with patients who received conventional consolidative and maintenance chemotherapy.12 In this study, approximately one third of the patients received their transplant in first complete remission. Whether stem cell transplantation will continue to have a role in the management of LBL in first complete remission is not known. Newer approaches, such as the application of pediatric ALL therapy to adult LBL,7 may result in low relapse rates, although that goal is not yet achieved in patients with very high risk features. Not surprisingly, the present study revealed that transplant recipients who had less advanced disease and good performance status were more likely to become long-term survivors. Overall survival was similar for both autologous and allogeneic transplant recipients, regardless of disease stage, bone marrow involvement, time from diagnosis to transplantation, or other potentially confounding factors. However, the pattern of treatment failure was different for the 2 groups. Treatment-related mortality was higher with allogeneic transplantation In the early months after transplantation, TRM was substantially higher in allogeneic than autologous transplant recipients, leading to a survival advantage with autologous transplantation through the first 6 months. A single explanation for higher TRM is not apparent. Reported causes of death included pneumonitis, infection, and organ failure. Although grade II-IV GVHD developed in 28% of allograft recipients, 47% of the patients with TRM were diagnosed with acute GVHD at some point prior to death. It is likely that GVHD contributed to mortality even though the proximate cause of death was reported as infection, organ failure, or pneumonitis. However, GVHD does not necessarily account for all the higher TRM between allograft or autograft recipients. Allograft recipients were more likely to receive radiation-containing conditioning regimens and use bone marrow as the source of stem cells. It is possible that these factors contributed to increased mortality through greater organ toxicity and/or slower engraftment, but proof to support this contention is lacking. Higher TRM but fewer relapses after allogeneic compared with autologous transplantation is observed in other comparative studies of transplantation for hematologic malignancies.30-33Relapses were less likely with allogeneic transplantation As expected, bone marrow involvement and advanced disease stage at transplantation were associated with relapse independent of transplant type. We found that an allogeneic source of stem cells was associated with a reduced risk of relapse, even though survival did not improve because of higher TRM. The observation of fewer relapses in allogeneic transplantation held true in multivariate analysis, after adjustment for the possibly confounding effects of age, sex, Karnofsky performance score at transplantation, disease stage at transplantation, chemosensitivity, bone marrow involvement at transplantation, central nervous system involvement, serum LDH level, initial chemotherapy given, use of TBI and growth factors, graft source, time from diagnosis to transplantation, and year of transplantation.Three possible explanations for this observation are suggested. First, a graft-versus-lymphoma effect provided protection against relapse. Although the existence of a GVL effect is supported by clinical observations,20-22 there are limited data for its activity in LBL. One prior report found relapse was less likely for patients with more advanced disease who received an allogeneic compared with autologous transplant. As in the present study, the antilymphoma benefit of an allogeneic transplantation was offset by higher TRM.14 In our study, we found that there were far fewer relapses after allogeneic than autologous transplantation, regardless of disease stage. We did not find a statistically significant protective effect of GVHD against relapse. However, it is also well documented that clinically evident GVHD is not a mandatory prerequisite for GVL.34 A second explanation is that reinfusion of autologous stem cells contaminated with tumor cells contributed to the higher relapse rate in the autologous transplant group. More than 90% of the stem cell collections were not purged, and, in any event, the effectiveness of purging to prevent reintroduction of lymphoma is not established. Finally, it is possible that the difference in the relapse rates may be that TRM in the allogeneic transplant group occurred preferentially in those destined to relapse. This current study suggests that, as practiced in the previous decade, the choice between allogeneic versus autologous stem cells made little difference in overall transplantation outcome, regardless of disease status or other important factors. However, the pattern of treatment failure differed and gives important clues as to future strategies. Because most patients lack an available allogeneic donor, new strategies to improve the outcome of autologous transplantation are needed. The lack of an obvious plateau in relapses after autologous transplantation indicates that late disease control is a major problem. Incorporation of current or future monoclonal antibody therapies, perhaps as posttransplantation consolidation, may be of value for these patients. Because TRM was the most important cause of treatment failure for the allogeneic patients, strategies to reduce TRM without compromising the GVL effect may be useful. Results from animal studies suggest that drug strategies that prevent GVHD while preserving GVL may be possible.35,36 Alternatively, modest reductions in conditioning intensity may decrease TRM without increasing the risk of relapse.37,38 However, the full measure of the toxicity associated with reduced intensity transplantation, such as GVHD, is not yet known, and reduction in intensity may compromise tumor control. Some centers are exploring high-dose therapy with autologous transplantation followed by reduced intensity allogeneic transplantation with promising results in certain settings, including high-risk lymphoma.39,40 A carefully designed clinical trial to test reduced intensity allogeneic transplantation for patients with lymphoblastic lymphoma may also be worth considering.
Submitted May 23, 2002; accepted September 27, 2002.
Prepublished online as Blood First Edition Paper, November 27, 2002; DOI 10.1182/blood-2002-05-1483.
Supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute; Contract No. CP-21161 from the National Cancer Institute of the US Department of Health and Human Services; Grant No. DAMD17-95-I-5002 from the Department of the US Army Medical Research and Development Command; and grants from Abgenix, AmCell Corporation, American Cancer Society, American Society of Clinical Oncology, Amgen, Anonymous, Aventis Pharmaceuticals, Berlex Laboratories, Blue Cross and Blue Shield Association, Lynde and Harry Bradley Foundation, Bristol-Myers Squibb Oncology, Center for Advanced Studies in Leukemia, Cerus, Chimeric Therapies, Chiron Therapeutics, Eleanor Naylor Dana Charitable Trust, Deborah J. Dearholt Memorial Fund, Empire Blue Cross Blue Shield, Fujisawa Healthcare, Gambro BCT, Genentech, GlaxoSmithKline, Human Genome Sciences, ICN Pharmaceuticals, IDEC Pharmaceuticals, Immunex, IntraBiotics Pharmaceuticals, Kettering Family Foundation, Kirin Brewery, Robert J. Kleberg Jr and Helen C. Kleberg Foundation, LifeTrac/Allianz, The Liposome Company, Nada and Herbert P. Mahler Charities, Market Certitude LLC, Mayer Ventures, MedImmune, Merck & Co, Milliman & Robertson, Milstein Family Foundation, The Greater Milwaukee Foundation/Elsa Schoeneich Research Fund, NeoRx, Nexell Therapeutics, Novartis Pharmaceuticals, Orphan Medical, Ortho Biotech, John Oster Family Foundation, Pfizer US Pharmaceuticals, Pharmacia, Principal Life Insurance Company, Response Oncology, RGK Foundation, Roche Laboratories, SangStat, Schering AG, Schering Oncology/Biotech, Stackner Family Foundation, The Starr Foundation, SuperGen, TheraTechnologies, Unicare Life & Health Insurance, and Wyeth/Genetics Institute.
A complete list of the members of the Lymphoma Study Writing Committee of the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry appears in the "Appendix."
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Mary M. Horowitz, IBMTR/ABMTR Statistical Center, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226; e-mail: marymh{at}mcw.edu.
1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-2795[Abstract]. 2. Nathwani BN, Diamond LW, Winberg CD, et al. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer. 1981;48:2347-2357[CrossRef][Medline] [Order article via Infotrieve].
3.
Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA.
Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia.
Blood.
1986;67:474-478
4.
Cossman J, Chused TM, Fisher RI, Magrath I, Bollum F, Jaffe ES.
Diversity of immunological phenotypes of lymphoblastic lymphoma.
Cancer Res.
1983;43:4486-4490
5.
Coleman CN, Picozzi VJ Jr, Cox RS, et al.
Treatment of lymphoblastic lymphoma in adults.
J Clin Oncol.
1986;4:1628-1637
6.
Hoelzer D, Gokbuget N, Digel W, et al.
Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
Blood.
2002;99:4379-4385 7. Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;3:1368-1376.
8.
Reiter A, Schrappe M, Ludwig WD, et al.
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
Blood.
2000;95:416-421
9.
Armitage JO.
Drug therapy: treatment of non-Hodgkin's lymphoma.
N Engl J Med.
1993;328:1023-1030
10.
Kobrinsky NL, Sposto R, Shah NR, et al.
Outcomes of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy and transplantation: Childrens Cancer Group study CCG-5912.
J Clin Oncol.
2001;19:2390-2396
11.
Anderson JR, Jenkin RDT, Wilson JF.
Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report from the Childrens Cancer Group.
J Clin Oncol.
1993;11:1024-1032
12.
Sweetenham JW, Santini G, Qian W, et al.
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
J Clin Oncol.
2001;19:2927-2936
13.
Bouabdallah R, Xerri L, Bardou V-J, et al.
Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center.
Ann Oncol.
1998;9:619-625
14.
Chopra R, Goldstone AH, Pearce R, et al.
Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data.
J Clin Oncol.
1992;10:1690-1695 15. De Witte T, Awwad B, Boezeman J, et al. Role of allogeneic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994;14:767-774[Medline] [Order article via Infotrieve]. 16. Sweetenham JW, Liberti G, Pearce R, et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol. 1994;12:1358-1365[Abstract].
17.
Phillips GL, Herzig RH, Lazarus HM, Fay JW, Griffith R, Herzig GP.
High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma.
J Clin Oncol.
1986;4:480-488 18. Eden OB, Hann I, Imeson J, Cotterill S, Gerrard M, Pinkerton CR. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol. 1992;82:310-316[Medline] [Order article via Infotrieve]. 19. van Besien KW, Mehra R, Giralt S, et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. Am J Med. 1996;100:299-307[CrossRef][Medline] [Order article via Infotrieve]. 20. Van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:977-982[CrossRef][Medline] [Order article via Infotrieve].
21.
Ratanatharathorn V, Uberti J, Karanes C, et al.
Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.
Blood.
1994;84:1050-1055 22. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759[CrossRef][Medline] [Order article via Infotrieve]. 23. National Hospital Discharge Survey for 1990 and 1991. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control. National Center for Health Statistics. Hospital Care Statistics Branch. 24. Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital & Health Statistics, Series 13: Data from the National Health Survey. Vol 108. Hyattsville, MD: US Department of Health and Human Services.; 1991:1-236.
25.
Curtis RE, Rowlings PA, Deeg HJ, et al.
Solid cancers after bone marrow transplantation.
N Engl J Med.
1997;336:897-904
26.
Silberman G, Crosse MG, Peterson EA, et al.
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries.
N Engl J Med.
1994;331:1063-1067 27. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:665-706. 28. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer Verlag; 1996:334-336. 29. Andersen PK, Klein JP, Zhang MH. Testing for center effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489-1500[CrossRef][Medline] [Order article via Infotrieve].
30.
Bjorkstrand BB, Ljungman P, Svensson H, et al.
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.
Blood.
1996;88:4711-4718
31.
Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH.
Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease.
J Clin Oncol.
1996;14:1291-1296
32.
Cassileth PA, Harrington DP, Appelbaum FR, et al.
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
N Engl J Med.
1998;339:1649-1656 33. Varterasian M, Janakiraman N, Karanes C, et al. Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol. 1997;20:462-466[CrossRef][Medline] [Order article via Infotrieve].
34.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562
35.
Krijanovski OI, Hill GR, Cooke KR, et al.
Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Blood.
1999;94:825-831 36. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589[Medline] [Order article via Infotrieve].
37.
Slavin S, Nagler A, Naparstek E, et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Blood.
1998;91:756-763
38.
Martino R, Caballero MD, Perez Simon JA, et al.
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Blood.
2002;100:2243-2245
39.
Kroger N, Schwerdtfeger R, Kiehl M, et al.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
Blood.
2002;100:755-760
40.
Carella AM, Cavaliere M, Lerma E, et al.
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
J Clin Oncol.
2000;18:3918-3924
The Lymphoma Study Writing Committee of the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry includes Asad Bashey, Brian J. Bolwell, Linda J. Burns, Mitchell S. Cairo, Richard E. Champlin, Cesar O. Freytes, John Gibson, Steve C. Goldstein, Mary J. Laughlin, John Lister, David I. Marks, Richard T. Maziarz, Alan M. Miller, Gustavo A. Milone, Santiago Pavlovsky, Andrew L. Pecora, J. Douglas Rizzo, Gary Schiller, Harry C. Schouten, and Mei Jie Zhang.
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Burkhardt, A. Reiter, E. Landmann, P. Lang, L. Lassay, R. Dickerhoff, M. Lakomek, G. Henze, and A. von Stackelberg Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group J. Clin. Oncol., July 10, 2009; 27(20): 3363 - 3369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hunault, M. Truchan-Graczyk, D. Caillot, J.-L. Harousseau, S. Bologna, C. Himberlin, D. Guyotat, C. Berthou, P. Casassus, L. Baranger, et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial Haematologica, December 1, 2007; 92(12): 1623 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Song, M. Barnett, R. Gascoyne, M Chhanabhai, D. Forrest, D. Hogge, J. Lavoie, S. Nantel, T. Nevill, J. Shepherd, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes Ann. Onc., March 1, 2007; 18(3): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Stock and N. L. Seibel Acute lymphoblastic leukemia and lymphoblastic lymphoma ASH Self-Assessment Program, January 1, 2007; 2007(1): 253 - 264. [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Kim, T. E. Tanimoto, N. Hirabayashi, S. Goto, M. Kami, S. Yoshioka, T. Uchida, K. Kishi, Y. Tanaka, A. Kohno, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Blood, July 1, 2006; 108(1): 382 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Duwe, D. H. Sterman, and A. I. Musani Tumors of the Mediastinum Chest, October 1, 2005; 128(4): 2893 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Ganti, P. J. Bierman, J. C. Lynch, R. G. Bociek, J. M. Vose, and J. O. Armitage Hematopoietic stem cell transplantation in mantle cell lymphoma Ann. Onc., April 1, 2005; 16(4): 618 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ballen and R. P. Hasserjian Case 15-2004 - A 31-Year-Old Man with Bilateral Testicular Enlargement N. Engl. J. Med., May 13, 2004; 350(20): 2081 - 2087. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
